IWWD
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
Phase observationalN = 880
- Population
- Patients with rectal cancer and a clinical complete response after neoadjuvant treatment, managed by watch-and-wait
- Design
- Descriptive analysis of an international multicentre registry of pooled individual patient data from 47 institutes in 15 countries. Of 1009 patients who received neoadjuvant treatment and were managed by watch-and-wait, 880 (87%) with a clinical complete response were analysed. Not randomised.
- Arms
- Clinical complete response, watch-and-wait (experimental, n = 880): Neoadjuvant treatment followed by watch-and-wait (surgery omitted)
- People
- van der Valk MJM, IWWD Consortium
Show the numbers
| Endpoint | Analysis | Clinical complete response, watch-and-wait | Control | Effect |
|---|---|---|---|---|
| Cumulative incidence of local regrowthPatients with a clinical complete response (880)Two-year cumulative incidence of local regrowth | finalmedian follow-up 3.3 yearsvan 2018 | 25.2% at 2 y (22.2–28.5%) | — | The abstract states that 88% of local regrowth was diagnosed in the first 2 years and 97% was located in the bowel wall. |
| Cumulative incidence of distant metastasesPatients with a clinical complete response (880)Proportion of patients diagnosed with distant metastases (no time point given in the abstract) | finalmedian follow-up 3.3 yearsvan 2018 | 8% | — | 71 of 880 patients. |
| OSPatients with a clinical complete response (880)Five-year overall survival | finalmedian follow-up 3.3 yearsvan 2018 | 85% at 5 y (80.9–87.7%) | — | — |
| Disease-specific survivalPatients with a clinical complete response (880)Five-year disease-specific survival | finalmedian follow-up 3.3 yearsvan 2018 | 94% at 5 y (91–96%) | — | — |
| Endpoint | Analysis | Clinical complete response, watch-and-wait | Control | Effect |
|---|---|---|---|---|
| Cumulative incidence of local regrowthPatients with a clinical complete response (880)Two-year cumulative incidence of local regrowth | finalmedian follow-up 3.3 yearsvan 2018 | 25.2% at 2 y (22.2–28.5%) | — | The abstract states that 88% of local regrowth was diagnosed in the first 2 years and 97% was located in the bowel wall. |
| Cumulative incidence of distant metastasesPatients with a clinical complete response (880)Proportion of patients diagnosed with distant metastases (no time point given in the abstract) | finalmedian follow-up 3.3 yearsvan 2018 | 8% | — | 71 of 880 patients. |
| OSPatients with a clinical complete response (880)Five-year overall survival | finalmedian follow-up 3.3 yearsvan 2018 | 85% at 5 y (80.9–87.7%) | — | — |
| Disease-specific survivalPatients with a clinical complete response (880)Five-year disease-specific survival | finalmedian follow-up 3.3 yearsvan 2018 | 94% at 5 y (91–96%) | — | — |
Appears in
Sources
van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537-2545.